Bernadette Lázár

The Nonsteroidal Anti-Inflammatory Drug Ketorolac Alters the Small Intestinal Microbiota and Bile Acids Without Inducing Intestinal Damage or Delaying Peristalsis in the Rat

Barbara Hutka, Bernadette Lázár, András S. Tóth, Bence Ágg et autres

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) induce significant damage to the small intestine, which is accompanied by changes in intestinal bacteria (dysbiosis) and bile acids. However, it is still a question of debate whether besides mucosal inflammation also other factors, such as direct …

hu (code pays fourni par la source)

A comprehensive time course and correlation analysis of indomethacin-induced inflammation, bile acid alterations and dysbiosis in the rat small intestine

Bernadette Lázár, Szilvia B. László, Barbara Hutka, András S. Tóth et autres

It has been proposed that changes in microbiota due to nonsteroidal anti-inflammatory drugs (NSAIDs) alter the composition of bile, and elevation of hydrophobic secondary bile acids contributes to small intestinal damage. However, little is known about the effect of NSAIDs on small …

hu (code pays fourni par la source)

Chronic treatment with rofecoxib but not ischemic preconditioning of the myocardium ameliorates early intestinal damage following cardiac ischemia/reperfusion injury in rats

Szilvia B. László, Bernadette Lázár, Gábor B. Brenner, András Makkos et autres

There is some recent evidence that cardiac ischemia/reperfusion (I/R) injury induces intestinal damage within days, which contributes to adverse cardiovascular outcomes after myocardial infarction. However, it is not clear whether remote gut injury has any detectable early signs, and whether different interventions …

hu (code pays fourni par la source)

Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

Gábor B. Brenner, András Makkos, Csilla Terézia Nagy, Zsófia Onódi et autres

Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of 'hidden cardiotoxicity' is defined as cardiotoxicity of a drug that manifests in the diseased (e.g. ischemic/reperfused), …

hu, de (code pays fourni par la source)

Efficacy-Based Perspective to Overcome Reduced Opioid Analgesia of Advanced Painful Diabetic Neuropathy in Rats

Mihály Balogh, Ferenc Zádor, Zoltán Zádori, Mohammed A. Shaqura et autres

Reduction of the opioid analgesia in diabetic neuropathic pain (DNP) results from µ-opioid receptor (MOR) reserve reduction. Herein, we examined the antinociceptive and antiallodynic actions of a novel opioid agonist 14-O-methymorphine-6-O-sulfate (14-O-MeM6SU), fentanyl and morphine in rats with streptozocin-evoked DNP of 9-12 …

hu, de (code pays fourni par la source)

Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat

Bernadette Lázár, Gábor B. Brenner, András Makkos, Mihály Balogh et autres

Intestinal dysbiosis is linked to numerous gastrointestinal disorders, including inflammatory bowel diseases. It is a question of debate if coxibs, selective inhibitors of cyclooxygenase (COX)-2, cause dysbiosis. Therefore, in the present study, we aimed to determine the effect of long-term (four weeks) …

hu (code pays fourni par la source)

Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)

Aurélien Marabelle, François Ghiringhelli, Maha Ayyoub, Éric Tartour et autres

Background: Immune-targeted monoclonal antibodies blocking inhibitory immune checkpoints such as CTLA-4, PD-1 and PD-L1 have shown durable responses in multiple tumour types. These drugs generate a new type of complications in oncology: immune-related adverse events (ImAE). There is no established predictive biomarker …

fr (code pays fourni par la source)

Similar and Distinct Mechanisms in the Protective Processes of Upper and Lower Gastrointestinal Tract

K. Gyires, S László, Bernadette Lázár, Zoltán Zádori

Gastrointestinal (GI) mucosal integrity is based on the balance of aggressive and protective mechanisms. Mucosal damage may occur when the injurious factors become dominant or the mucosal defensive processes are impaired. The main target of the therapy against GI mucosal injury is …

hu (code pays fourni par la source)

The Peripheral Versus Central Antinociception of a Novel Opioid Agonist: Acute Inflammatory Pain in Rats

Mihály Balogh, Zoltán Zádori, Bernadette Lázár, Dávid Árpád Karádi et autres

hu, de (code pays fourni par la source)

Chronic cyclooxygenase-2 inhibition does not cause gastrointestinal damage in the rat

Bernadette Lázár, Gábor B. Brenner, Mihály Balogh, Szilvia B. László et autres

Background: It is known that nonsteroidal anti-inflammatory drugs (NSAIDs) may cause gastric and duodenal ulceration, but over the past decades it has become increasingly recognized that the distal parts of the small intestine are also harmed. The pathomechanism of this enteropathy is …

hu (code pays fourni par la source)

Rofecoxib, in contrast to celecoxib, does not have direct antimicrobial effect and does not cause small intestinal dysbiosis in the rat

Zoltán Zádori, Bernadette Lázár, Gábor B. Brenner, Szilvia B. László et autres

Background: Nonsteroidal anti-inflammatory drugs were shown to induce small intestinal dysbiosis by causing a shift from Gram-positive to predominantly Gram-negative bacteria. This dysbiosis may contribute significantly to the development of small intestinal mucosal injury. It is, however, still not clear whether selective …

hu (code pays fourni par la source)

14-O-Methylmorphine: A Novel Selective Mu-Opioid Receptor Agonist with High Efficacy and Affinity

Ferenc Zádor, Mihály Balogh, András Váradi, Zoltán Zádori et autres

hu (code pays fourni par la source)